Ley; Arthur Charles
Patent Applications and Registrations
Patent applications and USPTO patent grants for Ley; Arthur Charles.The latest application filed is for "prevention and reduction of blood loss".
- Ley; Arthur Charles - Newton MA
| Patent | Date |
|---|---|
| Prevention and reduction of blood loss Grant 11,344,610 - Ladner , et al. May 31, 2 | 2022-05-31 |
| Prevention And Reduction Of Blood Loss App 20190247477 - Ladner; Robert Charles ; et al. | 2019-08-15 |
| Prevention and reduction of blood loss Grant 10,245,307 - Ladner , et al. | 2019-04-02 |
| Prevention And Reduction Of Blood Loss App 20160361395 - Ladner; Robert Charles ; et al. | 2016-12-15 |
| Directed evolution of novel binding proteins Grant 7,893,007 - Ladner , et al. February 22, 2 | 2011-02-22 |
| Directed Evolution Of Novel Binding Proteins App 20090234101 - LADNER; ROBERT CHARLES ; et al. | 2009-09-17 |
| Directed evolution of disulfide-bonded micro-proteins Grant 7,413,537 - Ladner , et al. August 19, 2 | 2008-08-19 |
| Directed Evolution Of Novel Binding Proteins App 20070259417 - Ladner; Robert Charles ; et al. | 2007-11-08 |
| Directed evolution of novel binding proteins Grant 7,208,293 - Ladner , et al. April 24, 2 | 2007-04-24 |
| Method of recovering a nucleic acid encoding a proteinaceous binding domain which binds a target material Grant 7,118,879 - Ladner , et al. October 10, 2 | 2006-10-10 |
| ITI-D1 Kunitz domain mutants as hNE inhibitors App 20060134087 - Ley; Arthur Charles ; et al. | 2006-06-22 |
| Directed evolution of disulfide-bonded micro-proteins App 20060084113 - Ladner; Robert Charles ; et al. | 2006-04-20 |
| Directed evolution of novel binding proteins Grant 6,979,538 - Ladner , et al. December 27, 2 | 2005-12-27 |
| Enterokinase cleavage sequences Grant 6,906,176 - Ley , et al. June 14, 2 | 2005-06-14 |
| Method of recovering a nucleic acid encoding a proteinaceous binding domain which binds a target material App 20040023205 - Ladner, Robert Charles ; et al. | 2004-02-05 |
| Nucleic acids, genetic constructs, and library of nucleic acids encoding fusion proteins App 20040005539 - Ladner, Robert Charles ; et al. | 2004-01-08 |
| Kunitz domain mutants as cathepsin G inhibitors App 20030223977 - Ley, Arthur Charles ; et al. | 2003-12-04 |
| Fusion proteins, modified filamentous bacteriophage, and populations or libraries of same App 20030219722 - Ladner, Robert Charles ; et al. | 2003-11-27 |
| Directed evolution of novel binding proteins App 20030219886 - Ladner, Robert Charles ; et al. | 2003-11-27 |
| ITI-D1 Kunitz domain mutants as hNE inhibitors App 20030175919 - Ley, Arthur Charles ; et al. | 2003-09-18 |
| Directed evolution of novel binding proteins App 20030113717 - Ladner, Robert Charles ; et al. | 2003-06-19 |
| Novel enterokinase cleavage sequences App 20020192789 - Ley, Arthur Charles ; et al. | 2002-12-19 |
| Directed evolution of novel binding proteins App 20020150881 - Ladner, Robert Charles ; et al. | 2002-10-17 |
| Directed evolution of novel binding proteins Grant 5,837,500 - Ladner , et al. November 17, 1 | 1998-11-17 |
| Engineered human-derived kunitz domains that inhibit human neutrophil elastase Grant 5,663,143 - Ley , et al. September 2, 1 | 1997-09-02 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 